TY - JOUR
T1 - Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%.
AU - Metro, Giulio
AU - Banna, Giuseppe Luigi
AU - Signorelli, Diego
AU - Gili, Alessio
AU - Galetta, Domenico
AU - Galli, Giulia
AU - Economopoulou, Panagiota
AU - Roila, Fausto
AU - Friedlaender, Alex
AU - Camerini, Andrea
AU - Christopoulou, Athina
AU - Cantale, Ornella
AU - De Toma, Alessandro
AU - Pizzutilo, Pamela
AU - Jimenez, Beatriz
AU - Collazo-Lorduy, Ana
AU - Calles, Antonio
AU - Baxevanos, Panagiotis
AU - Linardou, Helena
AU - Kosmidis, Paris
AU - Giannarelli, Diana
AU - Mountzios, Giannis
AU - Addeo, Alfredo
N1 - Place: United States
PY - 2020/12/1
Y1 - 2020/12/1
N2 - The authors conducted a multicenter retrospective study on the outcome of programmed death-ligand 1 tumor proportion score≥50small cell lung cancer patients treated with first-line pembrolizumab according to the presence/absence of brain metastases. A total of 282 patients were included, of whom 56 had brain metastases that were treated with upfront local radiation therapy in 80.39.24.4P=0.48), respectively, while intracranial response rate and intracranial disease control rate were 67.55.0 respectively. The median time-to-treatment failure (TTF) and overall survival (OS) were 4.2 and 9.9 months versus 10.8 and 26.5 months for patients with and without brain metastases (P=0.06 and 0.05, respectively). Drug discontinuation rate due to treatment-related adverse events was 10.70.2 respectively. Multivariate analysis showed that baseline steroids was an independent predictor for a worse OS (Ptextless0.001), while performance status (PS)≥2 was an independent predictor for a poorer TTF (Ptextless0.001) and OS (Ptextless0.001). In patients with brain metastases, only PS ≥2 was predicted for a worse TTF (P=0.02) and OS (P=0.03). Pembrolizumab has activity against brain metastases from non-small cell lung cancers with programmed death-ligand 1≥50 and PS ≥2 seems to be the only factor associated with a worse outcome in patients with brain metastases.
AB - The authors conducted a multicenter retrospective study on the outcome of programmed death-ligand 1 tumor proportion score≥50small cell lung cancer patients treated with first-line pembrolizumab according to the presence/absence of brain metastases. A total of 282 patients were included, of whom 56 had brain metastases that were treated with upfront local radiation therapy in 80.39.24.4P=0.48), respectively, while intracranial response rate and intracranial disease control rate were 67.55.0 respectively. The median time-to-treatment failure (TTF) and overall survival (OS) were 4.2 and 9.9 months versus 10.8 and 26.5 months for patients with and without brain metastases (P=0.06 and 0.05, respectively). Drug discontinuation rate due to treatment-related adverse events was 10.70.2 respectively. Multivariate analysis showed that baseline steroids was an independent predictor for a worse OS (Ptextless0.001), while performance status (PS)≥2 was an independent predictor for a poorer TTF (Ptextless0.001) and OS (Ptextless0.001). In patients with brain metastases, only PS ≥2 was predicted for a worse TTF (P=0.02) and OS (P=0.03). Pembrolizumab has activity against brain metastases from non-small cell lung cancers with programmed death-ligand 1≥50 and PS ≥2 seems to be the only factor associated with a worse outcome in patients with brain metastases.
M3 - Article
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
SN - 1053-8550
IS - 9
ER -